Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

VNCE vs CURV vs XPOF vs RCUS vs VRA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VNCE
Vince Holding Corp.

Apparel - Manufacturers

Consumer CyclicalNASDAQ • US
Market Cap$61M
5Y Perf.-40.0%
CURV
Torrid Holdings Inc.

Apparel - Retail

Consumer CyclicalNYSE • US
Market Cap$160M
5Y Perf.-93.4%
XPOF
Xponential Fitness, Inc.

Leisure

Consumer CyclicalNYSE • US
Market Cap$244M
5Y Perf.-44.2%
RCUS
Arcus Biosciences, Inc.

Biotechnology

HealthcareNYSE • US
Market Cap$2.50B
5Y Perf.-21.1%
VRA
Vera Bradley, Inc.

Apparel - Footwear & Accessories

Consumer CyclicalNASDAQ • US
Market Cap$116M
5Y Perf.-62.4%

VNCE vs CURV vs XPOF vs RCUS vs VRA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VNCE logoVNCE
CURV logoCURV
XPOF logoXPOF
RCUS logoRCUS
VRA logoVRA
IndustryApparel - ManufacturersApparel - RetailLeisureBiotechnologyApparel - Footwear & Accessories
Market Cap$61M$160M$244M$2.50B$116M
Revenue (TTM)$296M$1.00B$299M$236M$270M
Net Income (TTM)$-18M$-7M$-34M$-369M$-48M
Gross Margin50.0%34.8%83.2%90.7%46.4%
Operating Margin-5.9%2.1%7.8%-168.6%-12.0%
Forward P/E10.9x
Total Debt$122M$149M$525M$99M$71M
Cash & Equiv.$607K$20M$46M$222M$19M

VNCE vs CURV vs XPOF vs RCUS vs VRALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VNCE
CURV
XPOF
RCUS
VRA
StockJul 21May 26Return
Vince Holding Corp. (VNCE)10060.0-40.0%
Torrid Holdings Inc. (CURV)1006.6-93.4%
Xponential Fitness,… (XPOF)10055.8-44.2%
Arcus Biosciences, … (RCUS)10078.9-21.1%
Vera Bradley, Inc. (VRA)10037.6-62.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: VNCE vs CURV vs XPOF vs RCUS vs VRA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CURV leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Vince Holding Corp. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. XPOF and RCUS also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
VNCE
Vince Holding Corp.
The Growth Leader

VNCE is the #2 pick in this set and the best alternative if growth and value is your priority.

  • 0.2% revenue growth vs VRA's -27.5%
  • Better valuation composite
Best for: growth and value
CURV
Torrid Holdings Inc.
The Quality Compounder

CURV carries the broadest edge in this set and is the clearest fit for quality and stability.

  • -0.7% margin vs RCUS's -156.4%
  • Beta 0.46 vs VNCE's 2.42
  • -1.7% ROA vs RCUS's -35.3%, ROIC 22.5% vs -64.1%
Best for: quality and stability
XPOF
Xponential Fitness, Inc.
The Growth Play

XPOF ranks third and is worth considering specifically for growth exposure.

  • Rev growth -1.7%, EPS growth 35.2%, 3Y rev CAGR 9.0%
  • 2.5% yield; the other 4 pay no meaningful dividend
Best for: growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder

RCUS is the clearest fit if your priority is long-term compounding.

  • 45.9% 10Y total return vs XPOF's -46.6%
  • +209.6% vs CURV's -70.9%
Best for: long-term compounding
VRA
Vera Bradley, Inc.
The Income Pick

VRA is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 3 yrs, beta 1.25
  • Lower volatility, beta 1.25, Low D/E 53.6%, current ratio 2.37x
  • Beta 1.25, current ratio 2.37x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthVNCE logoVNCE0.2% revenue growth vs VRA's -27.5%
ValueVNCE logoVNCEBetter valuation composite
Quality / MarginsCURV logoCURV-0.7% margin vs RCUS's -156.4%
Stability / SafetyCURV logoCURVBeta 0.46 vs VNCE's 2.42
DividendsXPOF logoXPOF2.5% yield; the other 4 pay no meaningful dividend
Momentum (1Y)RCUS logoRCUS+209.6% vs CURV's -70.9%
Efficiency (ROA)CURV logoCURV-1.7% ROA vs RCUS's -35.3%, ROIC 22.5% vs -64.1%

VNCE vs CURV vs XPOF vs RCUS vs VRA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VNCEVince Holding Corp.
FY 2024
Vince Wholesale
56.3%$165M
Vince Direct To Consumer
43.7%$128M
CURVTorrid Holdings Inc.
FY 2024
Apparel
89.6%$989M
Non-apparel
7.5%$83M
Other Products And Services
2.9%$32M
XPOFXponential Fitness, Inc.
FY 2025
Franchise
50.7%$193M
Product
11.2%$42M
Franchise Marketing Fund Revenue
9.6%$36M
Equipment Revenue
9.2%$35M
Service, Other
7.1%$27M
Merchandise Revenue
6.3%$24M
Franchise And Service Revenue
5.9%$22M
RCUSArcus Biosciences, Inc.
FY 2025
License And Development Services
87.4%$221M
Development Services
6.7%$17M
R&D Services
3.2%$8M
License
2.8%$7M
VRAVera Bradley, Inc.
FY 2025
Bags
39.0%$140M
Accessories
27.6%$99M
Travel
22.5%$81M
Home
8.0%$29M
Other Products
3.0%$11M

VNCE vs CURV vs XPOF vs RCUS vs VRA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLVNCELAGGINGVRA

Income & Cash Flow (Last 12 Months)

VNCE leads this category, winning 2 of 6 comparable metrics.

CURV is the larger business by revenue, generating $1.0B annually — 4.2x RCUS's $236M. CURV is the more profitable business, keeping -0.7% of every revenue dollar as net income compared to RCUS's -156.4%. On growth, VNCE holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
RevenueTrailing 12 months$296M$1.0B$299M$236M$270M
EBITDAEarnings before interest/tax-$16M$75M$35M-$391M-$4M
Net IncomeAfter-tax profit-$18M-$7M-$34M-$369M-$48M
Free Cash FlowCash after capex$13M-$22M-$3M-$489M$10M
Gross MarginGross profit ÷ Revenue+50.0%+34.8%+83.2%+90.7%+46.4%
Operating MarginEBIT ÷ Revenue-5.9%+2.1%+7.8%-168.6%-12.0%
Net MarginNet income ÷ Revenue-6.2%-0.7%-11.3%-156.4%-17.7%
FCF MarginFCF ÷ Revenue+4.3%-2.2%-1.1%-2.1%+3.7%
Rev. Growth (YoY)Latest quarter vs prior year+6.2%-14.3%-21.0%-39.3%-15.1%
EPS Growth (YoY)Latest quarter vs prior year-38.2%-185.7%+79.1%+10.5%+105.3%
VNCE leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

CURV leads this category, winning 2 of 5 comparable metrics.

On an enterprise value basis, XPOF's 7.9x EV/EBITDA is more attractive than CURV's 13.5x.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
Market CapShares × price$61M$160M$244M$2.5B$116M
Enterprise ValueMkt cap + debt − cash$183M$290M$723M$2.4B$168M
Trailing P/EPrice ÷ TTM EPS-3.16x-21.86x-4.45x-7.54x-2.42x
Forward P/EPrice ÷ next-FY EPS est.10.90x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple13.53x7.89x
Price / SalesMarket cap ÷ Revenue0.21x0.16x0.78x10.11x0.43x
Price / BookPrice ÷ Book value/share1.44x4.22x0.90x
Price / FCFMarket cap ÷ FCF3.41x9.86x11.49x
CURV leads this category, winning 2 of 5 comparable metrics.

Profitability & Efficiency

XPOF leads this category, winning 3 of 9 comparable metrics.

VNCE delivers a -34.4% return on equity — every $100 of shareholder capital generates $-34 in annual profit, vs $-69 for RCUS. RCUS carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to VNCE's 2.93x. On the Piotroski fundamental quality scale (0–9), VNCE scores 5/9 vs RCUS's 0/9, reflecting solid financial health.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
ROE (TTM)Return on equity-34.4%-69.0%-35.0%
ROA (TTM)Return on assets-7.5%-1.7%-9.5%-35.3%-18.9%
ROICReturn on invested capital-7.6%+22.5%+75.0%-64.1%-11.8%
ROCEReturn on capital employed-11.0%+11.4%+30.3%-42.1%-15.3%
Piotroski ScoreFundamental quality 0–953504
Debt / EquityFinancial leverage2.93x0.16x0.54x
Net DebtTotal debt minus cash$122M$129M$479M-$123M$52M
Cash & Equiv.Liquid assets$607,000$20M$46M$222M$19M
Total DebtShort + long-term debt$122M$149M$525M$99M$71M
Interest CoverageEBIT ÷ Interest expense-4.94x0.84x-0.24x-13.38x-71.04x
XPOF leads this category, winning 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RCUS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in RCUS five years ago would be worth $8,143 today (with dividends reinvested), compared to $634 for CURV. Over the past 12 months, RCUS leads with a +209.6% total return vs CURV's -70.9%. The 3-year compound annual growth rate (CAGR) favors RCUS at 7.7% vs XPOF's -39.1% — a key indicator of consistent wealth creation.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
YTD ReturnYear-to-date+13.8%+44.3%-18.5%+6.5%+60.5%
1-Year ReturnPast 12 months+182.2%-70.9%-22.6%+209.6%+120.2%
3-Year ReturnCumulative with dividends-21.2%-60.1%-77.4%+24.9%-22.3%
5-Year ReturnCumulative with dividends-60.3%-93.7%-46.6%-18.6%-62.5%
10-Year ReturnCumulative with dividends-91.9%-93.7%-46.6%+45.9%-75.1%
CAGR (3Y)Annualised 3-year return-7.6%-26.4%-39.1%+7.7%-8.1%
RCUS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CURV and VRA each lead in 1 of 2 comparable metrics.

CURV is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than VNCE's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRA currently trades 94.3% from its 52-week high vs CURV's 25.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
Beta (5Y)Sensitivity to S&P 5002.42x0.46x1.94x1.95x1.25x
52-Week HighHighest price in past year$5.90$6.08$11.14$28.72$4.39
52-Week LowLowest price in past year$1.02$0.94$3.83$7.06$1.39
% of 52W HighCurrent price vs 52-week peak+80.8%+25.2%+58.7%+86.3%+94.3%
RSI (14)Momentum oscillator 0–10064.135.248.460.561.4
Avg Volume (50D)Average daily shares traded171K852K626K1.2M344K
Evenly matched — CURV and VRA each lead in 1 of 2 comparable metrics.

Analyst Outlook

VRA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: CURV as "Hold", XPOF as "Buy", RCUS as "Buy", VRA as "Hold". Consensus price targets imply 22.3% upside for XPOF (target: $8) vs -1.3% for CURV (target: $2). XPOF is the only dividend payer here at 2.50% yield — a key consideration for income-focused portfolios.

MetricVNCE logoVNCEVince Holding Cor…CURV logoCURVTorrid Holdings I…XPOF logoXPOFXponential Fitnes…RCUS logoRCUSArcus Biosciences…VRA logoVRAVera Bradley, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuyHold
Price TargetConsensus 12-month target$1.51$8.00$30.00
# AnalystsCovering analysts10141820
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises103
Dividend / ShareAnnual DPS$0.16
Buyback YieldShare repurchases ÷ mkt cap+0.0%0.0%0.0%0.0%0.0%
VRA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

VNCE leads in 1 of 6 categories (Income & Cash Flow). CURV leads in 1 (Valuation Metrics). 1 tied.

Best OverallVince Holding Corp. (VNCE)Leads 1 of 6 categories
Loading custom metrics...

VNCE vs CURV vs XPOF vs RCUS vs VRA: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is VNCE or CURV or XPOF or RCUS or VRA a better buy right now?

For growth investors, Vince Holding Corp.

(VNCE) is the stronger pick with 0. 2% revenue growth year-over-year, versus -27. 5% for Vera Bradley, Inc. (VRA). Analysts rate Xponential Fitness, Inc. (XPOF) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — VNCE or CURV or XPOF or RCUS or VRA?

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -93. 7% for Torrid Holdings Inc. (CURV). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus CURV's -93. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — VNCE or CURV or XPOF or RCUS or VRA?

By beta (market sensitivity over 5 years), Torrid Holdings Inc.

(CURV) is the lower-risk stock at 0. 46β versus Vince Holding Corp. 's 2. 42β — meaning VNCE is approximately 430% more volatile than CURV relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 3% for Vince Holding Corp. — giving it more financial flexibility in a downturn.

04

Which is growing faster — VNCE or CURV or XPOF or RCUS or VRA?

By revenue growth (latest reported year), Vince Holding Corp.

(VNCE) is pulling ahead at 0. 2% versus -27. 5% for Vera Bradley, Inc. (VRA). On earnings-per-share growth, the picture is similar: Xponential Fitness, Inc. grew EPS 35. 2% year-over-year, compared to -174. 0% for Vince Holding Corp.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — VNCE or CURV or XPOF or RCUS or VRA?

Torrid Holdings Inc.

(CURV) is the more profitable company, earning -0. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is VNCE or CURV or XPOF or RCUS or VRA more undervalued right now?

Analyst consensus price targets imply the most upside for XPOF: 22.

3% to $8. 00.

07

Which pays a better dividend — VNCE or CURV or XPOF or RCUS or VRA?

In this comparison, XPOF (2.

5% yield) pays a dividend. VNCE, CURV, RCUS, VRA do not pay a meaningful dividend and should not be held primarily for income.

08

Is VNCE or CURV or XPOF or RCUS or VRA better for a retirement portfolio?

For long-horizon retirement investors, Torrid Holdings Inc.

(CURV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Vince Holding Corp. (VNCE) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CURV: -93. 7%, VNCE: -91. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between VNCE and CURV and XPOF and RCUS and VRA?

These companies operate in different sectors (VNCE (Consumer Cyclical) and CURV (Consumer Cyclical) and XPOF (Consumer Cyclical) and RCUS (Healthcare) and VRA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

XPOF pays a dividend while VNCE, CURV, RCUS, VRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

VNCE

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 29%
Run This Screen
Stocks Like

CURV

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 20%
Run This Screen
Stocks Like

XPOF

Income & Dividend Stock

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 49%
  • Dividend Yield > 1.0%
Run This Screen
Stocks Like

RCUS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 54%
Run This Screen
Stocks Like

VRA

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 27%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform VNCE and CURV and XPOF and RCUS and VRA on the metrics below

Revenue Growth>
%
(VNCE: 6.2% · CURV: -14.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.